Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of PF-08634404 with carboplatin and etoposide in previously untreated transformed small cell lung cancer
MOH_2026-03-29_015740Phase 2Not yet recruiting
- Sponsor
- Pfizer
- Start
- Mar 2026
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of PF-08634404 in small cell lung cancer (SCLC), sponsored by Pfizer. Primary endpoint: Safety and tolerability. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
PF-08634404
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on MOH_2026-03-29_015740.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2026-03-29_015740.